Frontiers in Immunology (Sep 2020)

Using Gene Editing Approaches to Fine-Tune the Immune System

  • Kristina Pavlovic,
  • Kristina Pavlovic,
  • María Tristán-Manzano,
  • Noelia Maldonado-Pérez,
  • Marina Cortijo-Gutierrez,
  • Sabina Sánchez-Hernández,
  • Pedro Justicia-Lirio,
  • Pedro Justicia-Lirio,
  • M. Dolores Carmona,
  • Concha Herrera,
  • Concha Herrera,
  • Francisco Martin,
  • Karim Benabdellah

DOI
https://doi.org/10.3389/fimmu.2020.570672
Journal volume & issue
Vol. 11

Abstract

Read online

Genome editing technologies not only provide unprecedented opportunities to study basic cellular system functionality but also improve the outcomes of several clinical applications. In this review, we analyze various gene editing techniques used to fine-tune immune systems from a basic research and clinical perspective. We discuss recent advances in the development of programmable nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)-Cas-associated nucleases. We also discuss the use of programmable nucleases and their derivative reagents such as base editing tools to engineer immune cells via gene disruption, insertion, and rewriting of T cells and other immune components, such natural killers (NKs) and hematopoietic stem and progenitor cells (HSPCs). In addition, with regard to chimeric antigen receptors (CARs), we describe how different gene editing tools enable healthy donor cells to be used in CAR T therapy instead of autologous cells without risking graft-versus-host disease or rejection, leading to reduced adoptive cell therapy costs and instant treatment availability for patients. We pay particular attention to the delivery of therapeutic transgenes, such as CARs, to endogenous loci which prevents collateral damage and increases therapeutic effectiveness. Finally, we review creative innovations, including immune system repurposing, that facilitate safe and efficient genome surgery within the framework of clinical cancer immunotherapies.

Keywords